I

    Intelligent Bio Solutions Inc. (INBS)

    Official site

    HEALTHCARE • MEDICAL DEVICES • NASDAQ

    $2.40
    +0.04 (+1.69%)

    Market Cap: $7.27M

    Last updated: Sep 01, 2026 at 5:00 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    37%(7/19)
    Avg Surprise
    -163.43%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-1.31
    Range$-1.31 - $-1.31
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-1.31
    Revenue Consensus
    $1M
    Range$1M - $1M
    1 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-1.36
    Range$-1.36 - $-1.36
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.00+100.0%
    60d ago$0.00+100.0%
    30d ago$0.00+100.0%
    7d ago$0.00+100.0%
    Current$-1.36
    Revenue Consensus
    $1M
    Range$1M - $1M
    1 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-1.36---
    Sep 26EST
    		-$-1.31---
    Jun 26
    Reported Aug 14
    		$-0.90$-1.58+43.04%Beat-104.5%
    Mar 26
    Reported May 13
    		$-1.80$1.40-228.57%Miss-309.1%
    Dec 25
    Reported Feb 12
    		$-2.82$-0.16-1662.50%Miss-464.0%
    Sep 25
    Reported Nov 12
    		$-0.35$-0.27-29.63%Miss+50.0%
    Jun 25
    Reported Aug 15
    		$-0.44$0.08-650.00%Miss+67.2%
    Mar 25
    Reported May 13
    		$-0.44$-0.10-340.00%Miss+96.9%
    Dec 24
    Reported Feb 13
    		$-0.50$-0.27-85.19%Miss+97.6%
    Sep 24
    Reported Nov 7
    		$-0.70$-0.53-32.08%Miss+32.7%
    Jun 24
    Reported Sep 19
    		$-1.34$-0.51-162.75%Miss+99.4%
    Mar 24
    Reported May 8
    		$-14.30$-8.70-64.37%Miss+97.9%
    Dec 23
    Reported Feb 9
    		$-20.70$-32.40+36.11%Beat+62.5%
    Sep 23
    Reported Nov 8
    		$-1.04N/A+86.45%Beat-1200.9%
    Jun 23
    Reported Aug 24
    		$-229.20$-178.80-28.19%Miss+31.8%
    Mar 23
    Reported May 11
    		$-686.40$-328.80-108.76%Miss-217.8%
    Dec 22
    Reported Feb 14
    		$-55.20N/A+79.09%Beat+90.0%
    Sep 22
    Reported Nov 9
    		$-0.08$-0.10+20.00%Beat+70.4%
    Jun 22
    Reported Aug 31
    		$-336.00$-432.00+22.22%Beat-479900.0%
    Mar 22
    Reported May 10
    		$-216.00$-384.00+43.75%Beat-79900.0%
    Dec 21
    Reported Feb 10
    		$-552.00$-384.00-43.75%Miss-239900.0%
    Sep 21
    Reported Nov 12
    		$-0.27N/AN/ABeat-200.0%
    Jun 21
    Reported Sep 15
    		$-0.07N/AN/ABeat+63.2%
    Mar 21
    Reported May 13
    		$-0.27$0.00N/AMiss-
    Dec 20
    Reported Mar 31
    		$-0.23$0.00N/AMiss-
    Sep 19
    Reported Nov 29
    		$-0.09$0.00N/AMiss-
    Jun 19
    Reported Jul 5
    		$-0.19$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-0.41EV/EBITDA-0.91x
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin-294.90%Operating Margin-346.00%
    ROE-307.70%ROICN/A
    Financial Health
    Debt/EquityN/AInterest Coverage-156.95x
    Current Ratio2.11xQuick Ratio1.98x
    Trading Statistics
    Beta4.21Avg Volume101.08K
    52-Week High$24.9052-Week Low$1.52

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.52
    SMA 20$2.42
    SMA 50$2.20
    SMA 200$4.50
    EMA 10$2.43
    EMA 20$2.39
    EMA 50$2.36
    EMA 200$4.95

    MACD

    Line: 0.07Signal: 0.11Hist: -0.04

    ADX

    ADX: 20.7+DI: 22.1-DI: 19.2

    Aroon & PSAR

    Aroon Up60.0
    Aroon Down4.0
    PSAR$3.02

    Bollinger Bands

    Upper Band$3.31
    Lower Band$1.54
    %B Position7282%(Upper)
    Band Width0.49

    RSI (14-Day)

    Neutral
    51.3

    Momentum Oscillators

    Stoch %K23.8
    Stoch %D23.9
    Williams %R-73.6
    ROC (10d)-28.8%
    Momentum-0.97
    CCI (20d)-6.5
    MFI (14d)56.9

    Volatility Measures

    ATR (14d)$0.26(10.7%)
    StdDev (20d)0.44
    Hist Vol159.4%(High)

    Volume Flow

    VWAP$2.38
    OBV114.5M
    AD Line8.6B
    CMF (20d)0.257

    Volume Metrics

    Avg Vol (20d)104.3K
    Vol Ratio0.2x(Low)
    VWMA (20d)$2.69

    Pivot Points

    R3$2.55
    R2$2.48
    R1$2.42
    Pivot Point$2.34
    S1$2.28
    S2$2.21
    S3$2.15

    Advanced Oscillators

    TSI7.44
    Ultimate Osc45.6
    KST309.53

    Financial Data

    QuarterMar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023
    Total Revenue$1.06M$896,774$1.11M$843,884$728,867$607,494$872,287$727,824$823,800$764,063$796,094$443,135
    Cost of Revenue$525,421$437,035$593,506$508,307$387,499$384,381$525,486$-87,734$645,311$564,815$563,763$393,560
    Gross Profit$535,381$459,739$518,291$335,577$341,368$223,113$346,801$815,558$178,489$199,248$232,331$49,575
    Operating Expenses$3.48M$3.10M$3.52M$3.44M$2.90M$2.49M$3.07M$3.63M$3.13M$2.19M$2.76M$2.75M
    R&D$0$0$0$0$0$0$0$0$0$0$0$0
    SG&A$2.46M$2.34M$2.66M$2.72M$2.41M$1.81M$1.95M$2.67M$2.43M$1.71M$2.46M$2.43M
    Operating Income$-2,947,101$-2,635,738$-2,999,593$-3,101,616$-2,560,329$-2,264,482$-2,725,261$-2,811,717$-2,953,735$-1,991,357$-2,526,365$-2,702,495
    Interest Income$49,444$5,334$8,504$9,058$17,687$21,937$52,840$70,534$10,640$3,509$139$89
    Interest Expense$4,241$56,209$3,903$10,061$7,919$13,502$22,327$54,550$42,674$32,468$37,448$59,577
    Income Before Tax$-2,869,640$-2,686,613$-2,994,992$-3,102,616$-2,550,674$-2,256,797$-2,694,799$-2,795,360$-2,986,765$-1,976,383$-2,432,424$-2,671,389
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-2,869,640$-2,686,613$-2,994,992$-3,102,616$-2,550,674$-2,256,797$-2,694,799$-2,795,360$-2,986,765$-1,976,383$-2,432,424$-2,671,389
    EBITDA$-2,624,450$-2,064,915$-2,696,215$-2,828,785$-2,263,611$-1,957,597$-2,422,201$-2,523,658$-2,627,205$-1,657,111$-2,087,555$-2,594,078
    EBIT$-2,914,843$-2,635,738$-2,999,593$-3,129,083$-2,560,442$-2,265,232$-2,725,312$-2,811,344$-2,954,731$-1,947,424$-2,395,115$-2,611,901
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about INBS

    News

    Intelligent Bio Solutions Achieves Above 98% Accuracy in Method Comparison Study, Supporting Planned 2026 FDA 510(k) Submission

    Intelligent Bio Solutions Inc. announced that its Intelligent Fingerprinting Drug Screening System achieved over 98% accuracy in its latest Method Comparison Study for detecting the opiate codeine. This multi-site clinical study demonstrated significantly improved sensitivity (above 94%) and maintained 100% specificity, strengthening the company's planned FDA 510(k) submission in September 2026 for U.S. market entry. The results are crucial for workplace drug testing applications, ensuring reliable detection with minimal false positives.

    The Manila Times•9/1/26•
    Bullish

    Intelligent Bio Solutions reports improved drug screening accuracy

    Intelligent Bio Solutions Inc. announced improved accuracy for its Intelligent Fingerprinting Drug Screening System in detecting codeine. A multi-site clinical study achieved 98.2% accuracy, 94.6% sensitivity, and 100% specificity, a significant improvement from previous results. The company plans to submit its FDA 510(k) application in September 2026, leveraging these results.

    Investing.com•9/1/26•
    Bullish

    INBS Looks 0.4% Overvalued on GF Value™

    Intelligent Bio Solutions Inc (INBS) reported a GAAP loss per share but a 38.4% revenue increase, with the stock trading at $2.73, slightly above its GF Value™ of $2.72, suggesting a 0.4% overvaluation. Despite revenue growth, the company remains unprofitable with a low GF Score™ of 48/100, indicating financial distress and high bankruptcy risk due to a negative Altman Z-Score. The Price-to-Sales ratio is below historical and industry medians, reflecting market skepticism despite innovative technology.

    GuruFocus•8/20/26•
    Bearish

    Press Release: Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

    Intelligent Bio Solutions announced a 38% year-over-year revenue increase for fiscal year 2026, primarily fueled by the expansion of its reader installed base and high-margin cartridge sales. This growth highlights the company's strong performance in the market.

    Moomoo•8/20/26•
    Bullish

    Intelligent Bio Solutions Reports Fiscal 2026 Full-Year Revenue Growth of 38% Year-over-Year, Driven by Reader Installed Base and High-Margin Cartridge Growth

    Intelligent Bio Solutions announced a 38% year-over-year revenue growth for fiscal year 2026, primarily driven by an expanding reader installed base and increased sales of high-margin cartridges. This growth highlights the company's successful strategy in scaling its proprietary technology. The report indicates strong market adoption and operational efficiency.

    Moomoo•8/20/26•
    Bullish

    Frequently Asked Questions About INBS

    Does INBS pay dividends?
    Intelligent Bio Solutions Inc. (INBS) does not currently pay a regular dividend.
    What is INBS's market cap?
    Intelligent Bio Solutions Inc. (INBS) has a market capitalization of $7.27M with a current stock price of $2.40.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In